HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • tLNPplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文
HighField Biopharmaceuticals
  • Home
  • Platforms
    • ADCplex Platform
    • TCEplex Platform
    • tLNPplex Platform
  • Pipeline
    • K16: Immune Modulator
    • K1: Lipid-based Antibody Drug Complex
    • HF50: T cell Engager
    • HFG!: GLP-1R Agonist
  • Facilities
  • About
  • News & Publications
  • Contact
  • zh_CN简体中文

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc
glelit, sed do eiusmod tempor incididunt .ut labo
et dolore magna aliqua.

Blog Categories

  • HighField in the News (4)
  • Press Release (18)
  • Publications (16)
  • References (21)
  • Uncategorized (6)
  • Video (1)

Recent Posts

December 4, 2025

HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting

by PJWCreative
Post placeholder image
November 9, 2025

SITC 2025 Poster: Targeting MDSCs with HF1K16 Unlocks Long-Term Survival in Refractory Recurrent Glioma: an update of NCT05388487

by HighField Bio
Post placeholder image
November 9, 2025

SITC 2025 Poster: First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demontrates Tolerability and Early Clinical Response

by HighField Bio
October 31, 2025

Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 – 9, 2025.

by HighField Bio
Post placeholder image
July 31, 2025

Video 1 Test

by PJWCreative
April 21, 2025

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

by HighField Bio

Recent Comments

No comments to show.

Tags

General HF50 HFG1 K1 K16

Post placeholder image
December 28, 2016 in References

Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
March 15, 2016 in References

Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
October 27, 2015 in References

Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
March 30, 2009 in References

Myeloid-derived suppressor cells as regulators of the immune system

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
September 5, 2008 in References

Preclinical Manufacture of an Anti-HER2 scFv-PEG-DSPE, Liposome-Inserting Conjugate. 1. Gram-Scale Production and Purification

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
September 5, 2008 in Publications

Preclinical Manufacture of an Anti-HER2 scFv-PEG-DSPE, Liposome-Inserting Conjugate. 1. Gram-Scale Production and Purification

PJWCreative 0 Like Post Comments Off on Preclinical Manufacture of an Anti-HER2 scFv-PEG-DSPE, Liposome-Inserting Conjugate. 1. Gram-Scale Production and Purification
Read More
Post placeholder image
September 18, 2006 in References

All-trans-Retinoic Acid Improves Differentiation of Myeloid Cells and Immune Response in Cancer Patients

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
July 3, 2006 in References

Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
August 5, 2003 in References

Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers.

PJWCreative 0 Like Post 0 Comment
Read More
Post placeholder image
May 7, 1996 in References

Mechanism of DNA Release from Cationic Liposome/DNA Complexes Used in Cell Transfection

PJWCreative 0 Like Post 0 Comment
Read More
Prev1…4567Next

Download Company Profile

Home
Platforms
Pipeline
Facilities
About
News & Publications

Contact Us

Follow Us

Linkedin Weixin

© 2023-25 HighField Biopharmaceuticals, Inc.   Terms of Use.       
LipoADCplex™ and TRAFsome™ are trademarks of HighField Biopharmaceuticals, Inc

en_US English
en_US English
zh_CN 简体中文